HTX-011 Administration Study in Planned Caesarean Section Procedure

Inclusion Criteria: * Is expected, at the time of Screening visit, to deliver a single neonate. * Is scheduled to undergo a planned C-section surgery with a low transverse skin incision (eg, Pfannenstiel). * Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III. * Agrees to practice abstinence or use double-barrier contraception in the event of sexual activity and commits to the use of an acceptable form of birth control for 30 days after HTX-011 administration. * Agrees to refrain from the use of breast milk from this pregnancy in any manner. Exclusion Criteria: * Has planned to breastfeed her neonate at any time during the 28-day period after HTX-011 administration. * Has had a prior full-term pregnancy with unsuccessful breast milk expression. * Has a planned concurrent surgical procedure. * Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications. * Has been administered bupivacaine within 5 days prior to the scheduled surgery. * Has been administered any local anesthetic within 72 hours prior to the scheduled surgery. * Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug. * Has initiated treatment with study medications within 1 month prior to study drug administration that can impact pain control. * Has taken any NSAIDs within least 10 days prior to the scheduled surgery. * Has current significant placental abnormality/complications including, but not limited to, placenta previa or placenta accreta. * Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments. * Has uncontrolled anxiety, psychiatric, or neurological disorder. * Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix. * Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. * Previously participated in an HTX-011 study. * Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives. * Weight is \<50 kg at the time of Screening visit. * In the Investigator's judgment, subject is likely to have been morbidly obese prior to her pregnancy.